Showing results (51-60 of 63) with videos related to
Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialPeter Mohr, Axel Hauschild, Uwe Trefzer, et al.Oncotarget|November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trialSelma Ugurel, Carmen Loquai, Patrick Terheyden, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsDaniel E Speiser, Katrin Schwarz, Petra Baumgaertner, et al.European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaPaolo A Ascierto, David Minor, Antoni Ribas, et al.The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.The Lancet. Oncology|May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialMichael R Migden, Alexander Guminski, Ralf Gutzmer, et al.Journal of the American Academy of Dermatology|April 13, 2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinomaReinhard Dummer, Alexander Guminski, Ralf Gutzmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaAntoni Ribas, Richard Kefford, Margaret A Marshall, et al.The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.Pageof 7